|
1）Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. 1984; 2: 1055-8
|
|
|
|
2）Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986; 315: 341-7
|
|
|
|
|
3）Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991; 324: 1633-9
|
|
|
|
|
|
4）Oates-Whitehead RM, Baumer JH, Haines L, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2003; CD004000
|
|
|
|
|
|
5）佐地 勉，薗部友良，上村 茂，他．川崎病急性期治療のガイドライン．日本小児科学会雑誌．2003; 107: 1713-5
|
|
|
|
|
6）中村好一，上原里程，屋代真弓．第21回川崎病全国調査結果（www.jichi.ac.jp/dph/kawasakibyou/20110915/mcls21report.pdf）
|
|
|
|
|
|
7）Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2007; 166: 131-7
|
|
|
|
|
|
8）Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2006; 149: 237-40
|
|
|
|
|
|
9）Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006; 113: 2606-12
|
|
|
|
|
|
10）Seki M, Kobayashi T, Kobayashi T, et al. External validation of a risk score to predict intravenous immunoglobulin resistance in patients with Kawasaki disease. Pediatr Infect Dis J. 2011; 30: 145-7
|
|
|
|
|
|
11）Okada K, Hara J, Maki I, et al. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur J Pediatr. 2009; 168: 181-5
|
|
|
|
|
|
12）Ogata S, Ogihara Y, Honda T, et al. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Pediatrics. 2012; 129: e17-23
|
|
|
|
|
|
13）Kobayashi T, Inoue Y, Otani T, et al. Risk stratification in the decision to include pred-nisolone with intravenous immunoglobulin in pri-mary therapy of Kawasaki disease. Pediatr Infect Dis J. 2009; 28: 498-502
|
|
|
|
|
|
14）Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012; 379: 1613-20
|
|
|
|
|
|
15）Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 2007; 356: 663-75
|
|
|
|
|
|
16）Okada Y, Shinohara M, Kobayashi T, et al. Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children. J Pediatr. 2003; 143: 363-7
|
|
|
|
|
|
17）Ogata S, Ogihara Y, Nomoto K, et al. Clinical score and transcript abundance patterns identify Kawasaki disease patients who may benefit from addition of methylprednisolone. Pediatr Res. 2009; 66: 577-84
|
|
|
|
|
|
18）川崎富作．指趾の特異的落屑を伴う小児の急性熱性皮膚粘膜淋巴腺症候群（自験例50例の臨床的観察）．アレルギー．1967; 16: 178-222
|
|
|
|
|